Hillstream Biopharma (NASDAQ:CNTN) Downgraded to Sell Rating by Wall Street Zen

Hillstream Biopharma (NASDAQ:CNTN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Separately, Weiss Ratings raised shares of Hillstream Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hillstream Biopharma Price Performance

Hillstream Biopharma stock traded up $0.09 during mid-day trading on Friday, reaching $2.38. The stock had a trading volume of 641,379 shares, compared to its average volume of 1,261,309. The firm has a market cap of $183.55 million, a P/E ratio of -2.07 and a beta of 1.42. The company’s 50-day moving average price is $3.01. Hillstream Biopharma has a one year low of $1.08 and a one year high of $9.08.

Insider Buying and Selling

In other Hillstream Biopharma news, Director Gary S. Stetz sold 12,500 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $3.47, for a total value of $43,375.00. Following the completion of the transaction, the director owned 134,175 shares of the company’s stock, valued at approximately $465,587.25. The trade was a 8.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.34% of the company’s stock.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.